Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Interleukin and Geisinger collaborate in obesity research
The goal of the collaboration is to develop a series of genetic tests that will help physicians better understand an individual’s inherited resistance to weight loss and, more
The goal of the collaboration is to develop a series of genetic tests that will help physicians better understand an individual’s inherited resistance to weight loss and, more
The agreement will begin on October 1, 2008 and run for a three-year term. The agreement is said to offer Amerinet’s membership competitive market pricing, and access to
The trial, called Oracle MS will evaluate the safety and efficacy of two dosage regimens of cladribine tablets versus placebo in the treatment of patients who have experienced
The combination of this gene with Amsterdam Molecular Therapeutics’s (AMT) proprietary adeno-associated virus gene therapy platform could potentially allow the development of an effective, long-term treatment for this
Both Novo Nordisk and BioGeneriX are existing collaborative partners of Neose. Certain intellectual property rights, including those related to producing glycolipids, have been retained by Neose for future
Karin Hamberg, who is currently executive vice president of drug delivery research and alliance & project management, will assume responsibility for clinical, regulatory, and medical affairs undertaking Dr
The new results from the Crystel study show that after taking Enbrel for a year, either as continuous or intermittent therapy, patients experienced significant skin clearance as well
Mr Lechleiter, president and CEO of Lilly, will succeed outgoing chairman Sidney Taurel, who had previously announced his retirement from the company and the board, effective December 31,
The primary endpoint of the trial was the percentage of participants achieving at least a 75% reduction in psoriasis at week 12 as measured by the Psoriasis Area
In relapsing-remitting multiple sclerosis patients who switched from placebo to laquinimod, 52% reduction in the mean number of GdE lesions was observed (p